| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 07/07/2005 | WO2005039495A3 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies |
| 07/07/2005 | WO2005030265A3 Optical imaging of endometriosis |
| 07/07/2005 | WO2004109181A3 Device having a location for holding hyperpolarized inert gas |
| 07/07/2005 | WO2004042353A8 Identifying therapeutic compounds based on their physical-chemical properties |
| 07/07/2005 | US20050148772 Methods and compositions for detecting polynucleotide duplex damage and errors |
| 07/07/2005 | US20050148656 Carboxylic derivates |
| 07/07/2005 | US20050148512 Medical implants and fibrosis-inducing agents |
| 07/07/2005 | US20050147988 Recombinant protein for use as tool in detection of helicobacter infection; immunodiagnostics |
| 07/07/2005 | US20050147664 Comprising one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof; active agents preferably have a particle size of about 2 microns or less; for targeting delivery of the active agents to a desired site |
| 07/07/2005 | US20050147643 Treating varicose or veins by injecting a composition silk made of polyalkylene oxide-polyester block copolymer into the lumen of a vein; anchoring implantable medical devices into or onto biological tissue |
| 07/07/2005 | US20050147599 Medical implants and fibrosis-inducing agents |
| 07/07/2005 | US20050147563 Imaging lymph nodes with a Gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7-(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecane; in vivo contrast media in nuclear spin tomography; blood-pool agents, lymphographic agents |
| 07/07/2005 | US20050147562 for treating or preventing gastroesophageal reflux disease (GERD) |
| 07/07/2005 | US20050147560 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control |
| 07/07/2005 | US20050147557 Diagnostic agents for pancreatic exocrine function |
| 07/07/2005 | DE20023659U1 Molekulare Marker zum Testen der phänotypischen Stabilität von Zellpopulationen und Zellpopulationen für die autologe Transplantation Molecular markers for testing the phenotypic stability of cell populations and populations of cells for autologous transplantation |
| 07/07/2005 | CA2550900A1 Methods for detecting markers associated with endometrial disease or phase |
| 07/06/2005 | EP1550464A1 Stabilized microbubble composition for ultrasound |
| 07/06/2005 | EP1549354A2 Ratios of collagen peptides, their uses and products |
| 07/06/2005 | EP1549317A1 Improved imaging agents comprising barbituric acid derivatives |
| 07/06/2005 | CN1635910A Treatment and diagnosis of macrophage mediated disease |
| 07/06/2005 | CN1635855A Systems and methods for targeted magnetic resonance imaging of the vascular system |
| 07/06/2005 | CN1634600A Ultrasonic contrast medium with echo for stomach and intestine |
| 07/06/2005 | CN1634599A Method for screening anti-kinetosis medicine |
| 07/06/2005 | CN1634598A Construction method for mouse skin allergy animal model |
| 07/06/2005 | CN1634119A Liquid embolism agent for intracranial aneurysm and its preparing process |
| 07/06/2005 | CN1209167C Supersonic contrast medium and method for preparing supersonic contrast medium simultaneously as medicine and gene target carrier |
| 07/05/2005 | US6913743 Near infrared imaging agent |
| 07/05/2005 | CA2362429C Method and system for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response |
| 07/05/2005 | CA2129663C Biosynthetic binding protein for cancer marker |
| 06/30/2005 | WO2005059564A1 Rbp4 in insulin sensitivity/resistance, diabetes, and obesity |
| 06/30/2005 | WO2005059550A1 Dna encoding snorf138 and uses thereof |
| 06/30/2005 | WO2005059517A2 Toll-like receptor assays |
| 06/30/2005 | WO2005059118A2 Stem cell targeting using magnetic particles |
| 06/30/2005 | WO2005058375A1 Mri contrast medium composition for oral administration |
| 06/30/2005 | WO2005058374A1 Methods and compositions for modulating tau in vivo |
| 06/30/2005 | WO2005058373A2 Methods, program products, and systems for single and multi-agent dosing |
| 06/30/2005 | WO2005058372A1 Optical imaging contrast agents for imaging lung cancer |
| 06/30/2005 | WO2005058371A1 Optical imaging contrast agents |
| 06/30/2005 | WO2005058370A1 Optical imaging contrast agents for imaging lung cancer |
| 06/30/2005 | WO2005058360A2 Radiation therapy and medical imaging using uv emitting nanoparticles |
| 06/30/2005 | WO2005058153A2 Optical imaging contrast agents comprising a targeting vector linked to a fluorophore |
| 06/30/2005 | WO2005025508A3 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 06/30/2005 | WO2004112590A3 Methods of enhancing radiation effects with metal nanoparticles |
| 06/30/2005 | WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 06/30/2005 | US20050144659 Animals and cells containing a mutated alpha2delta gene |
| 06/30/2005 | US20050144656 treating fruitflies (Drosophila melanogaster) with medium containing strychnine, pentylenetetrazol, tetraethylammonium chloride, lithium carbonate and nicotine, then crossing to produce inheritable changes in locomotor behavior |
| 06/30/2005 | US20050144654 treating fruitfly Drosophila melanogaster adult males with fly medium containing either of neuroactive compounds strychnine, pentylenetetrazol, pilocarpine hydrochloride, tetraethylammonium chloride, lithium carbonate and ethosuximide, subjecting flies to negative geotaxis and horizontal locomotor assays |
| 06/30/2005 | US20050143656 Cavity-filling biopsy site markers |
| 06/30/2005 | US20050143336 Prevent or reduce inflammation secondary to administration of a lipid-nucleic acid complex in a subject by co-administering a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent with the lipid-nucleic acid complex |
| 06/30/2005 | US20050143327 Used to ameliorate oxidative stress diseases eg neurodegenerative diseases |
| 06/30/2005 | US20050142556 Molecular lymphatic mapping of sentinel lymph nodes |
| 06/30/2005 | US20050142533 Compositions and methods for promoting nerve regeneration |
| 06/30/2005 | US20050142163 Treatment for an orthopedic condition using agents such as silk or bleomycin |
| 06/30/2005 | US20050142068 Retinal toxicity screening methods |
| 06/30/2005 | US20050142066 Compounds or agents that inhibit and induce the formation of focal microvessel dilatations |
| 06/30/2005 | US20050142063 Detect low frequency surface changes utilizing modified microspheres; exposing surface; microspheres selectively adhere to any targeted surface marker; dislodging adherent microparticles with folic acid; mouthwash for oral cancer detection |
| 06/30/2005 | US20050142061 Radiofluorination methods |
| 06/30/2005 | CA2550084A1 Stem cell targeting using magnetic particles |
| 06/30/2005 | CA2548285A1 Rbp4 in insulin sensitivity/resistance, diabetes, and obesity |
| 06/29/2005 | EP1548454A1 Apparatus for hydrogenation |
| 06/29/2005 | EP1548123A1 Methods of screening agents for activity using teleosts |
| 06/29/2005 | EP1548027A1 Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient |
| 06/29/2005 | EP1547619A2 Preparation of diagnostic agents |
| 06/29/2005 | EP1546704A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/29/2005 | EP1546373A2 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis |
| 06/29/2005 | EP1546364A2 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry |
| 06/29/2005 | EP1546359A2 Site-specific labeling of affinity tags in fusion proteins |
| 06/29/2005 | EP1546320A2 Nanoengineered biophotonic hybrid device |
| 06/29/2005 | EP1546305A2 Implantable artificial organ devices |
| 06/29/2005 | EP1546203A2 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| 06/29/2005 | EP1546092A2 Agents for imaging and diagnostic methods using them |
| 06/29/2005 | EP1545705A2 Flexible and/or elastic brachytherapy seed or strand |
| 06/29/2005 | EP1545629A1 Bifunctional contrast agent comprising a fluorescent dye and an mri contrast agent |
| 06/29/2005 | EP1545628A2 Biochemical methods for measuring metabolic fitness of tissues or whole organisms |
| 06/29/2005 | EP1545610A2 Epitope sequences |
| 06/29/2005 | EP1545520A1 Multifunctional cox-2 inhibitors |
| 06/29/2005 | EP1545502A2 Keto cannabinoids with therapeutic indications |
| 06/29/2005 | EP1330639B1 Material which is provided with an nmr contrast agent and method for producing the same |
| 06/29/2005 | EP1025216B1 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 06/29/2005 | CN1631444A Ultrasound contrast medium composition with phospholipid as membrane material and its preparation method |
| 06/29/2005 | CN1208338C Contrast enhancement agent of magnetic resonance imaging radiography for metal fullerene as well as its preparing method and usage |
| 06/28/2005 | US6911457 Diabetes imaging probes |
| 06/28/2005 | US6911219 Compositions injectable via a catheter to form occlusive masses in a selected body region; highly dispersed in a liquid medium of given specific gravity; nonclumping in the delivery equipment during embolization |
| 06/23/2005 | WO2005057222A2 Use of t-cadherin as a target |
| 06/23/2005 | WO2005056049A1 Methods and compounds for modulating triglyceride and vldl secretion |
| 06/23/2005 | WO2005041860A3 Stem cells for use in locating and targeting tumor cells |
| 06/23/2005 | WO2005037312A3 Binding molecules for the extra-domain b of fibronectin, used for the detection of atherosclerotic plaques |
| 06/23/2005 | WO2005030254A3 Conjugates for photodynamic therapy |
| 06/23/2005 | WO2005004592A9 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications |
| 06/23/2005 | WO2004110279A9 Blood flow estimates through replenishment curve fitting in ultrasound contrast imaging |
| 06/23/2005 | US20050137806 Characterizing biological stimuli by response curves |
| 06/23/2005 | US20050137180 Porphrins or azaporprins for photosensitizing therapy or photodetection with azaporprins for cardiovascular disorders and coordination with metals |
| 06/23/2005 | US20050136069 Immunogenic portion of Mycobacterium tuberculosis proteins and monophosphoryl lipid A as adjuvant; vaccines |
| 06/23/2005 | US20050136054 Humanised antibodies |
| 06/23/2005 | US20050136008 Polybiotin compounds for magnetic resonance imaging and drug delivery |
| 06/23/2005 | US20050136007 water soluble cyanine dyes used in medical diagnosis; radiology |
| 06/23/2005 | US20050136006 Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule |
| 06/23/2005 | US20050136003 Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use |
| 06/23/2005 | US20050136002 Use of particulate contrast agents in diagnostic imaging for studying physiological paramaters |